• Nanoparticle In Vivo Transfection Reagent
  • Astrocyte
  • Kidney In Vivo Transfection
  • Pegylated Liposome

Shop Products

Category Archives: Xenograft

Validated Breast Cancer Xenograft Models

Altogen Labs is a GLP-compliant biotech laboratory that specializes in oncology research studies and provides preclinical testing of new medicines that often require a sequence of experiments utilizing various scientific methods to demonstrate novel compound anti-cancer efficacy, safety, and mechanism of action. Breast cancer is the second leading cancer that causes death in women globally, and cancer itself is the second leading cause of death for women. It is highly dangerous due to the speed at which it spreads throughout the body. While survival rates may be increasing due to increased screening and treatments, it remains lethal and one of the most prominent cancers in women. To accelerate oncology drug development, Altogen Labs offers over 100 established PDX and CDX xenograft models.

All breast cancer xenograft models available at Altogen Labs are in-house validated and provide essential tools to test the efficacy and safety of novel breast cancer medications. These xenograft models are generated by the xenotransplantation of human tumorigenic breast cancer cells under the skin of immunocompromised mice (subcutaneous) or via orthotopic injection of breast cancer cells into the mammary fat pad of mice in order to study tumor growth. Altogen Labs offers many PDX models and 11 CDX validated breast cancer xenograft animal models with individual characteristics (ER, HER-2/neu, PR, EGFR, KRAS, BRCA1-2, TP53, FGFR1-4, BRAF, NRAS, etc) to serve a variety of different research needs: 4T1,  BT474,  HS578T,  KPL-4,  MCF-7,  MDA-MB-157,  MDA-MB-231,  MDA-MB-453,  MDA-MB-468,  T47D. Xenograft studies allow a similar representation of human pathology to study cellular events, providing scientists with an in vivo model of tumor behavior that allows greater insight and data for research. Xenotransplantation studies create an effective environment for the evaluation of pharmaceutical compounds and the studying of cell behavior and screening of cancer therapies. This is an essential step that provides necessary information and evaluations in the pharmaceutical development process.

About Altogen Labs

Altogen Labs is a biology CRO company, headquartered in Austin, Texas that provides safety and efficacy testing for novel anti-cancer medicines. Preclinical services include safety in vivo toxicology studies (for IND applications), efficacy studies (for regulatory submissions), drug discovery (for patent applications), and many other types of R&D pharm/tox, biodistribution, and xenograft efficacy studies.


Crossing Blood-Brain Barrier and In Vivo Delivery of Negatively Charged Biomolecules into Glioblastoma Enabled by Altogen's Nanoparticle In Vivo Transfection Reagent

LAS VEGAS, NEVADA – July 19, 2021 – Altogen Biosystems, leading manufacturer of in vivo transfection products, announced today that Altogen’s nanoparticle-based in vivoTransfection reagent (catalog #5031) was demonstrated to be effective for glioblastoma-targeted co-delivery of plasmid DNA (3.7 kb) and chemically modified siRNA. This transfection reagent was used in over 30 research publications, demonstrating highly… Continue Reading

Nanoparticle In Vivo Transfection Reagent (Altogen)

July 27, 2021 – Altogen Biosystems® is a biotechnology manufacturing company that specializes in the development and testing of optimized cell transfection reagents and kits for both in vitro and in vivo delivery. In 2018 Altogen Biosystems launched the AltoFect transfection reagent formulated for difficult-to-transfect cells (like B-cells, T-cells), and primary cell cultures that are… Continue Reading

cGMP-grade Nanoparticle Transfection Reagent for In Vivo Delivery

Altogen Biosystems is a manufacturer of life science research products that includes in vivo transfection reagents designed for tissue-targeted delivery of biomolecules. Altogen’s Nanoparticle In Vivo Transfection Reagent was launched in 2008 and used in over 30 research publications demonstrating highly efficient delivery of cargo nucleic acids (siRNA, microRNA, mRNA, plasmid DNA, and small proteins)… Continue Reading